Detailed Narrative
Strong Financial Performance Driven by Davaindia
Zota Health Care reported a robust financial year 2025, with consolidated revenue from operations growing by an impressive 62% year-on-year to ₹292.98 crores, up from ₹180 crores in FY24. Gross profit also saw significant growth, increasing by 86% year-on-year to ₹155 crores. The Davaindia retail pharmacy chain was the primary growth driver, contributing ₹186 crores (64% of total revenue) with an 80% year-on-year growth. Domestic sales grew 11% to ₹63 crores, while the export business expanded 59% to ₹32 crores.
Aggressive Davaindia Network Expansion
The Davaindia network expanded significantly, reaching 1,582 operational stores by March 31, 2025, from just three stores initially. In FY25 alone, the company added 702 new stores, with a strategic focus on scaling its Company-Owned Company-Operated (COCO) format, opening 599 new COCO stores. The Gross Merchandise Value (GMV) for Davaindia rose sharply to ₹245 crores from ₹137 crores, indicating increased customer engagement and larger basket sizes. The company aims to add approximately 800 to 900 more COCO stores in the current financial year (FY26).
Gross Margin Dynamics and Store Relocations
The company's gross margin for Q4 FY25 was approximately 50%, a dip from previous levels, primarily attributed to the closure of 18-19 COCO stores and associated inventory losses. Management clarified that this impact is limited to a single quarter and expects gross margins to improve steadily going forward⏳. Store closures are strategic, mainly occurring when rental costs for older stores become excessively high (e.g., ₹1.5-2 lakhs per month), prompting relocation to more viable locations to ensure long-term sustainability and profitability.
Strategic Product Expansion and Off-Patent Opportunities
Zota Health Care's product strategy focuses on chronic diseases, and while injectables are not a current priority due to their in-hospital usage, the company plans to expand into insulin and other diabetes-related therapies. The company actively tracks off-patent opportunities, as demonstrated by the rapid launch of their version of Empagliflozin shortly after its patent expiry. This approach ensures timely and affordable access to essential medicines for patients.
Supply Chain and Inventory Management
The company's supply chain is currently outsourced, but management is exploring opportunities for greater efficiency at a regional level, including the possibility of setting up child warehouses. Inventory days at the Surat central warehouse are currently around 80-90 days due to the high growth stage and new store openings. A new warehouse is planned for Delhi in the near future, which is expected to significantly improve fill rates, currently at 95-98%, and enhance supply chain capabilities for the Northern region.
E-commerce and Digital Initiatives
Zota Health Care has launched an online B2C platform via an app and website for Davaindia, offering over 2,000 SKUs with hyper-local delivery. The beta pilot for online sales started in April 2025 and has since moved to a full-fledged Android and iOS app. Management views the entry of general e-commerce players into the medicine space as an opportunity, emphasizing their specialization in generic-generic medicines and the Indian consumer's preference for dedicated pharmacies, which provides a competitive edge.